Departamento de Nutrição e Dietética, Irmandade Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brasil.
Departamento de Pediatria, Unidade de Endocrinologia Pediátrica, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brasil.
Arch Endocrinol Metab. 2022 Nov 17;66(6):815-822. doi: 10.20945/2359-3997000000526. Epub 2022 Oct 11.
The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity.
This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional guidance, and were followed for six months. In all patients the anthropometric assessment was carried out by a nutritionist and data on weight, height and waist circumference (WC) were collected. Body composition was assessed using dual emission X-ray absorptiometry (DXA).
After six months, both groups had increased weight, height but reduced body index mass (BMI) standard deviation score, with no differences between groups. After the intervention, both groups showed a reduction in the percentage of total body fat and an increase in lean mass, but only the placebo group showed a reduction in the percentage of trunk fat. However, the variation in these parameters did not differ between groups.
The probiotic group does not seem to have benefited from supplementation. However, we suggest that this reduction in BMI SDS in both groups may have occurred due to improvements in diet because of the nutritional advice given throughout the therapy. We concluded that supplementation with this strain of probiotic was not effective in promoting weight loss or improving the body composition of this population.
本研究旨在评估益生菌补充疗法对肥胖儿童和青少年的人体测量值和身体成分的影响。
这是一项非随机对照、前瞻性、双盲干预性临床试验,进行了主要数据分析。样本包括 44 名青春期肥胖儿童和青少年(8-17 岁)。患者被分配到益生菌(鼠李糖乳杆菌)或安慰剂组,按性别和实际年龄匹配。两组均接受营养指导,并随访 6 个月。所有患者均由营养师进行人体测量评估,并收集体重、身高和腰围(WC)数据。使用双能 X 射线吸收法(DXA)评估身体成分。
6 个月后,两组体重和身高均增加,但体重指数(BMI)标准差评分降低,两组间无差异。干预后,两组的总体脂肪百分比均降低,瘦体重增加,但只有安慰剂组的躯干脂肪百分比降低。然而,这些参数的变化在两组间没有差异。
益生菌组似乎没有从补充中受益。然而,我们建议两组 BMI SDS 的降低可能是由于治疗过程中给予的营养建议改善了饮食。我们得出结论,补充这种益生菌菌株对该人群的体重减轻或身体成分改善没有效果。